1555_Bhatt.pdf

1、Renal Denervation:Update for 2025Deepak L.Bhatt,MD,MPH,MBA,FACC,FAHA,FESC,MSCAI Director of Mount Sinai Fuster Heart HospitalDr.Valentin Fuster Professor of Cardiovascular Medicine,Icahn School of Medicine at Mount SinaiDisclosuresDr.Bhatt discloses the following relationships-Advisory Board:Angiowa

2、ve,Antlia Bioscience,Bayer,Boehringer Ingelheim,CellProthera,Cereno Scientific,E-Star Biotech,High Enroll,Janssen,Level Ex,McKinsey,Medscape Cardiology,Merck,NirvaMed,Novo Nordisk,Repair Biotechnologies,Stasys,Tourmaline Bio;Board of Directors:American Heart Association New York City,Angiowave(stock

3、 options),Bristol Myers Squibb(stock),DRS.LINQ(stock options),High Enroll(stock);Consultant:Alnylam,Altimmune,Broadview Ventures,Corcept Therapeutics,Corsera,GlaxoSmithKline,Hims,SERB,SFJ,Summa Therapeutics;Worldwide Clinical Trials;Data Monitoring Committees:Acesion Pharma,Assistance Publique-Hpita

4、ux de Paris,Baim Institute for Clinical Research,Boston Scientific(Chair,PEITHO trial),Cleveland Clinic,Contego Medical(Chair,PERFORMANCE 2),Duke Clinical Research Institute,Mayo Clinic,Mount Sinai School of Medicine(for the ABILITY-DM trial,funded by Concept Medical;for ALLAY-HF,funded by Alleviant

5、 Medical),Novartis,Population Health Research Institute;Rutgers University(for the NIH-funded MINT Trial);Honoraria:American College of Cardiology(Senior Associate Editor,Clinical Trials and News,ACC.org;Chair,ACC Accreditation Oversight Committee),Arnold and Porter law firm(work related to Sanofi/B

6、ristol-Myers Squibb clopidogrel litigation),Baim Institute for Clinical Research(AEGIS-II executive committee funded by CSL Behring),Belvoir Publications(Editor in Chief,Harvard Heart Letter),Canadian Medical and Surgical Knowledge Translation Research Group(clinical trial steering committees),CSL B